All In Biotech

Drug Trial Radar · NCT07167966

Alzheimer's Tau Platform: Regimen A - AADvac1

Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

450

Planned (sponsor's estimate)

Start

Nov 3, 2026

Primary completion

Aug 31, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
Paul S. AisenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Axon Neuroscience SE; University of California, San Francisco; Massachusetts General Hospital; Alzheimer's Therapeutic Research Institute; Alzheimer's Clinical Trials Consortium; National Institute on Aging (NIA)
First posted
Sep 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.

Conditions

  • Preclinical Alzheimer's Disease
  • Prodromal Alzheimer's Disease
  • Alzheimer Disease

Interventions

  • AADvac1Drug

    Subcutaneous injection of AADvac1

  • DonanemabDrug

    Active comparator: intravenous infusion of donanemab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of brain tau deposition as measured by tau positron emission tomography (PET)Time frame: 0, 6, 18 and 30 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Banner Alzheimer's Institute

    Phoenix, Arizona

  • University of California, San Francisco (UCSF), Memory and Aging Center

    San Francisco, California

  • University of Kentucky Sanders Brown Center on Aging

    Lexington, Kentucky

  • Brigham and Women's Hospital, Center for Alzheimer's Research and Treatment

    Boston, Massachusetts

  • Butler Hospital Memory and Aging Program

    Providence, Rhode Island

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Harborview Medical Center, University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.